Diabetes, obesity & metabolism
The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.
Mario Luca Morieri, Monica Vedovato, Benedetta Maria Bonora, Paola Fioretto, Gian Paolo Fadini
Published: 202610.1111/dom.70445
Abstract
AIMS: To determine whether the sequence of initiation between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) influences kidney outcomes in people with type 2 diabetes (T2D) receiving these t…
Preview only. Read the full abstract at the source